dupilumab
regeneron,sanofi
['dupixent']
press release: dupixent late-breaking phase 3 data at eadv 2022 showed significant improvements in signs and symptoms of prurigo nodularis $paris:san 
Run by investors, for investors.

Real-time:
PRs
Gov. contract awards
Earnings
M&As
FDA approvals
Insider trades
SEC filings
And more

Not investment advice